LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
E. Morand(Monash Health), Shalabh Singhal(Integrated BioTherapeutics (United States)), JT Merrill(Oklahoma Medical Research Foundation), Brian J. Sharkey(Bristol-Myers Squibb (United States)), Margaret N. Pike, V. Shah(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), V. P. Werth(Philadelphia VA Medical Center), Coburn Hobar(Bristol-Myers Squibb (United States)), T. Wegman(Bristol-Myers Squibb (United States)), Ian M. Catlett(Bristol-Myers Squibb (United States)), Sibabrata Banerjee(Bristol-Myers Squibb (United States)), Ronald van Vollenhoven(Amsterdam University Medical Centers)
Cited by 19
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355
2021 DORIS definition of remission in SLE: final recommendations from an international task force
|Lupus Science & Medicine|2021|340